Projektin tiedot
Description
The blood-brain barrier (BBB) is a major obstacle in treating diseases of the central nervous system (CNS) such as Parkinson’s, Alzheimer’s, schizophrenia and brain cancer, affecting 180 million Europeans with less than 5% of current candidate drugs effectively reaching the brain. NAP4DIVE strives to revolutionize the traditionally expensive and inefficient drug development for these diseases by establishing advanced non-animal alternatives for testing and predicting nanoparticle (NP)-based drug delivery across the human BBB. This approach aligns with EU and global initiatives to reduce animal testing and advance human-based biomedical research models.
Akronyymi | NAP4DIVE |
---|---|
Tila | Käynnissä |
Todellinen alku/loppupvm | 01/01/25 → 31/12/28 |
Yhteistyöpartnerit
- Åbo Akademi (johto)
- Finnadvance Oy
- AstraZeneca Ab
- Göteborgin yliopisto
- Chalmersin teknillinen korkeakoulu
- Microfluidics Innovation Center
- Delft University of Technology
- HansaBioMed Life Sciences Ou
- Betthera s.r.o.
- AMIRES s.r.o.
- Eindhoven University of Technology
Rahoitus
- European Commission